Myoview (Tetrofosmin)

Tetrofosmin is a lipophilic cation that, when labeled with technetium‑99m, penetrates heart muscle cells and accumulates proportionally to regional blood flow. The emitted gamma photons are captured by a SPECT camera, producing detailed images of myocardial perfusion.

The specific dose of Myoview is determined by the prescribing physician based on the imaging protocol, patient characteristics, and the amount of technetium‑99m used. The prescriber sets the appropriate activity for each study.

The safety of Myoview in pregnancy and lactation has not been established. It should be used only if the potential diagnostic benefit justifies any potential risk to the fetus or infant, and appropriate precautions should be taken.

To order Myoview, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Myoview (tetrofosmin) and agents such as technetium‑99m sestamibi have similar mechanisms, both being lipophilic cations that image myocardial perfusion. Differences may include pharmacokinetic profiles, image quality under certain stress conditions, and specific regulatory approvals, which clinicians consider when selecting an agent.

Myoview should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. Follow all radiopharmacy handling guidelines to maintain product integrity and radiation safety.

Myoview is administered intravenously as an injectable solution. After reconstitution with technetium‑99m, the prepared dose is injected into a peripheral vein under controlled conditions, typically immediately before the imaging procedure.

Serious risks, although rare, include severe allergic reactions (anaphylaxis), profound hypotension, life‑threatening arrhythmias, acute myocardial infarction, and pulmonary edema. Immediate medical attention is required if any of these events occur.

Myoview should not be administered to patients with known hypersensitivity to tetrofosmin or technetium‑99m compounds, or to those in whom the diagnostic benefit does not outweigh potential risks, such as certain pregnant or lactating women without a clear indication.